Pharmaceutical Sciences Seminar Series

Glycan-centric approaches for cancer immunotherapy

(Drug DISCOVERY Specific Seminar)

• Peng Wu, PhD
• Scripps Research Institute

The development of immune checkpoint inhibitors based on anti-CTLA-4, anti-PD-1/PD-L1 has revolutionized cancer treatment. However, more than 50% of cancer patients fail to respond to anti-CTLA-4, anti-PD-1/PD-L1.

In this talk, I will discuss our recent progress in developing glycan-centric approaches for cancer immunotherapy, including FucoID, a proximity-based technique for identifying antigen-specific T cells, and bispecific T cell-engager-sialidase conjugates. I will also discuss how these new approaches can be combined with FDA-approved checkpoint blockade to achieve improved therapeutic efficacy in murine tumor models.

Hosted by Weiping Tang